Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Companya??) (TSXV: ATE, OTCQB:
ATBPF), a leader in developing safer therapeutics for pain and
inflammation, is pleased to announce the successful completion of part
one of the Phase 2B dose-ranging, efficacy study for its lead drug,
ATB-346. The study was conducted in 24 healthy volunteers who were
randomized to once daily doses of ATB-346 at 250 mg, 200 mg or 150 mg.

The primary objectives of the study were to: (i) evaluate
cyclo-oxygenase (COX) inhibition to inform the doses of ATB-346 to be
used in part two, the upcoming dose-ranging, efficacy study; (ii) obtain
a series of blood samples at distinct time intervals to facilitate
analysis of the principal metabolites of ATB-346; and (iii) further
assess the overall safety and tolerability of the drug.

The blood samples were successfully collected over the 7-day treatment
period. COX enzyme activity was assessed through the measurement of
thromboxane (TXB2) synthesis, a known biomarker that can be measured in
the blood. NSAIDs exert analgesic and anti-inflammatory effects through
inhibition of COX activity. The COX inhibition data of the 250 mg dose
was consistent with the Phase 2A and Phase 2B studies, and marked
inhibition was also observed with the two lower doses. This provides
management with confidence in the initial selection of the doses to be
used in the upcoming dose-ranging, efficacy study. Additionally,
comprehensive analysis is underway to characterize the pharmacokinetic
profile of each principal metabolite of ATB-346. The drug was also safe
and well tolerated.

Part two of the Phase 2B dose-ranging, efficacy study remains on track
to commence in January 2019 with a top-line data read-out anticipated in
Q2 2019. This will be a double-blind, placebo-controlled study and will
be conducted in approximately 250 osteoarthritis patients. The primary
objective is to evaluate the efficacy of three doses of ATB-346 in
reducing pain.

About ATB-346
ATB-346 is a hydrogen sulfide-releasing
derivative of naproxen. Nonsteroidal anti-inflammatory drugs ("NSAIDsa??)
are the most commonly used therapy for osteoarthritis, yet their use is
associated with a high incidence of gastrointestinal ulceration and
bleeding. NSAIDs are also widely used in conditions such as rheumatoid
arthritis, ankylosing spondylitis, gout, and general pain reduction,
with a similarly high rate of gastrointestinal ulceration and bleeding.
It is well-accepted that patients with these conditions would benefit
greatly from an effective, non-addictive, GI-sparing
anti-inflammatory/analgesic agent such as ATB-346.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Май 2022    »